Icaritin's Anti-Leukemia Effects on Chronic Myeloid Leukemia
Author Information
Author(s): Zhu Jian feng, Li Zi jian, Zhang Guang sen, Meng Kun, Kuang Wen yong, Li Jin, Zhou Xin fu, Li Rui juan, Peng Hong ling, Dai Chong wen, Shen Jian Kai, Gong Fan jie, Xu Yun xiao, Liu Su fang
Primary Institution: Division of Hematology, Institute of Molecular Hematology, The Second Xiang-Ya Hospital, Central South University, Changsha, Hunan, People's Republic of China
Hypothesis
To explore the effects of Icaritin on chronic myeloid leukemia (CML) cells and underlying mechanisms.
Conclusion
Icaritin from Chinese herb medicine may be a potential anti-CML agent with low adverse effect.
Supporting Evidence
- Icaritin inhibited proliferation of K562 cells with an IC50 of 8 µM.
- Icaritin induced apoptosis in CML cells as shown by Annexin V staining.
- Icaritin promoted erythroid differentiation of K562 cells.
- Icaritin reduced Jak-2, p-Stat3, and p-Akt expression.
- Icaritin prolonged the lifespan of NOD-SCID mice inoculated with K562 cells.
Takeaway
Icaritin is a natural compound that can help fight a type of blood cancer called chronic myeloid leukemia by stopping cancer cells from growing and helping them die.
Methodology
CML cells were treated with Icaritin, and cell proliferation and apoptosis were analyzed using MTT assay and Annexin V staining, respectively. In vivo effects were tested in NOD-SCID mice.
Potential Biases
Potential bias due to funding from a company that produces Icaritin.
Limitations
The study primarily focuses on in vitro and in vivo models, and further clinical studies are needed to confirm the findings.
Participant Demographics
24 CML patients (14 CML-CP and 10 CML-BC) and 11 healthy controls.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website